Correction
This article was originally published in The Gray Sheet
Executive Summary
Gen-Probe: In the Jan. 18, 2010 issue (1p. 14), a "J.P. Morgan Healthcare Conference In Brief" item incorrectly notes that Gen-Probe plans to submit a 510(k) to FDA for its Aptima HPV assay to run on its Tigris system. The company plans to submit a PMA
You may also be interested in...
J.P. Morgan Healthcare Conference In Brief
NxStage Medical: The Lawrenceville, Mass., company is planning to file a 510(k) for a nocturnal indication for its System One home hemodialysis system by March after recently wrapping up a clinical trial, CEO Jeff Burbank said during a Jan. 13 session at the J.P. Morgan Healthcare Conference in San Francisco. System One is indicated for home use, but not specifically nighttime use, and patients usually undergo five to six dialysis sessions per week, the exec noted. The NxStage device is the only home hemodialysis system cleared by FDA, but Baxter, already a leader in peritoneal dialysis, intends to launch its own home-based hemodialysis device in 2011 (1"The Gray Sheet" Sept. 21, 2009)
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.